Iron loading and oxidative stress in the Atm-/- mouse liver

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 300, Issue 4, 2011, Pages

  McDonald, Cameron J ^a   Ostini, Lesa ^a   Wallace, Daniel F ^a   John, Abraham N ^b   Watters, Dianne J ^a,b   Subramaniam, V Nathan ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Ataxia Telangiectasia; Ferroportin; Heme oxygenase 1; Hepcidin

Indexed keywords

FERRITIN; FERROPORTIN; HYDROXYL RADICAL; IRON; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TYROSINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; BIOACCUMULATION; BMP6 GENE; CATALYSIS; CONTROLLED STUDY; FERROPORTIN GENE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEME OXYGENASE (DECYCLING) 1 GENE; HEPCIDIN GENE; HFE GENE; IRON BLOOD LEVEL; LIVER; LYMPHATIC SYSTEM TUMOR; MALE; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATOR GENE; UPREGULATION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CATION TRANSPORT PROTEINS; CELL CYCLE PROTEINS; DIET; DNA-BINDING PROTEINS; FERRITINS; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; IMMUNOHISTOCHEMISTRY; IRON; IRON, DIETARY; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79955065672     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00486.2010     Document Type: Article

References (44)

1. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16: 879-895, 2009.
2. Barbouti A, Doulias PT, Zhu BZ, Frei B, Galaris D. Intracellular iron, but not copper, plays a critical role in hydrogen peroxide-induced DNA damage. Free Radic Biol Med 31: 490-498, 2001.
3. Barlow C, Dennery PA, Shigenaga MK, Smith MA, Morrow JD, Roberts LJ 2nd, Wynshaw-Boris A, Levine RL. Loss of the ataxiatelangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci USA 96: 9915-9919, 1999.
4. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. Atmdeficient mice: a paradigm of ataxia telangiectasia. Cell 86: 159-171, 1996.
5. Berndt C, Kurz T, Selenius M, Fernandes AP, Edgren MR, Brunk UT. Chelation of lysosomal iron protects against ionizing irradiation. Biochem J 432: 295-301, 2010.
6. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110: 401-408, 2007.
7. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser 19: 1-63, 1985.
8. Browne SE, Roberts LJ 2nd, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med 36: 938-942, 2004.
9. Bulmer AC, Ried K, Blanchfield JT, Wagner KH. The anti-mutagenic properties of bile pigments. Mutat Res 658: 28-41, 2008.
10. Chen G, Fillebeen C, Wang J, Pantopoulos K. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis 28: 785-791, 2007.
11. Chen P, Peng C, Luff J, Spring K, Watters D, Bottle S, Furuya S, Lavin MF. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice. J Neurosci 23: 11453-11460, 2003.
12. Choi JY, Neuhouser ML, Barnett MJ, Hong CC, Kristal AR, Thornquist MD, King IB, Goodman GE, Ambrosone CB. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29: 964-970, 2008.
13. Clark JE, Foresti R, Green CJ, Motterlini R. Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem J 348: 615-619, 2000.
14. Dennery PA, Spitz DR, Yang G, Tatarov A, Lee CS, Shegog ML, Poss KD. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 101: 1001-1011, 1998.
15. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1: 191-200, 2005.
16. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-Torres J, Leder P. Pleiotropic defects in ataxia-telangiectasia proteindeficient mice. Proc Natl Acad Sci USA 93: 13084-13089, 1996.
17. Gatei M, Shkedy D, Khanna KK, Uziel T, Shiloh Y, Pandita TK, Lavin MF, Rotman G. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. Oncogene 20: 289-294, 2001.
18. Gueven N, Luff J, Peng C, Hosokawa K, Bottle SE, Lavin MF. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med 41: 992-1000, 2006.
19. Heinloth AN, Shackelford RE, Innes CL, Bennett L, Li L, Amin RP, Sieber SO, Flores KG, Bushel PR, Paules RS. ATM-dependent and-independent gene expression changes in response to oxidative stress, gamma irradiation, and UV irradiation. Radiat Res 160: 273-290, 2003.
20. Huang ML, Becker EM, Whitnall M, Rahmanto YS, Ponka P, Richardson DR. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci USA 106: 16381-16386, 2009.
21. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K, Nakagata N, Ikeda Y, Mak TW, Suda T. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431: 997-1002, 2004.
22. Kamsler A, Daily D, Hochman A, Stern N, Shiloh Y, Rotman G, Barzilai A. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res 61: 1849-1854, 2001.
23. Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA, Naumann PW. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76: 991-995, 1990.
24. Kemp JD, Thorson JA, Stewart BC, Naumann PW. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res 52: 4144-4148, 1992.
25. Kim J, Wong PK. Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem Cells 27: 1987-1998, 2009.
26. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769, 2008.
27. Lu S, Shen KC, Wang Y, Brooks SC, Wang YA. Impaired hepatocyte survival and liver regeneration in Atm-deficient mice. Hum Mol Genet 14: 3019-3025, 2005.
28. McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PLoS One 5: e9594, 2010.
29. Milner JA, Romagnolo DF, Connor JR, Lee SY. Iron and Cancer. In: Bioactive Compounds and Cancer. Clifton, NJ: Humana, 2010, p. 469-496.
30. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26: 323-342, 2006.
31. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093, 2004.
32. Reichenbach J, Schubert R, Schindler D, Muller K, Bohles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 4: 465-469, 2002.
33. Reliene R, Fleming SM, Chesselet MF, Schiestl RH. Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food Chem Toxicol 46: 1371-1377, 2008.
34. Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Rahmanto YS. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. J Mol Med 88: 323-329, 2010.
35. Shackelford RE, Fu Y, Manuszak RP, Brooks TC, Sequeira AP, Wang S, Lowery-Nordberg M, Chen A. Iron chelators reduce chromosomal breaks in ataxia-telangiectasia cells. DNA Repair (Amst) 5: 1327-1336, 2006.
36. Shackelford RE, Manuszak RP, Johnson CD, Hellrung DJ, Link CJ, Wang S. Iron chelators increase the resistance of Ataxia telangeictasia cells to oxidative stress. DNA Repair (Amst) 3: 1263-1272, 2004.
37. Shackelford RE, Manuszak RP, Johnson CD, Hellrung DJ, Steele TA, Link CJ, Wang S. Desferrioxamine treatment increases the genomic stability of Ataxia-telangiectasia cells. DNA Repair (Amst) 2: 971-981, 2003.
38. Straud S, Zubovych I, De Brabander JK, Roth MG. Inhibition of iron uptake is responsible for differential sensitivity to V-ATPase inhibitors in several cancer cell lines. PLoS One 5: e11629, 2010.
39. Suttner DM, Dennery PA. Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J 13: 1800-1809, 1999.
40. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci 33: 9-11, 1968.
41. Vickers AE, Sinclair JR, Fisher RL, Morris SR, Way W. (2010) Blood cell oxidative stress precedes hemolysis in whole blood-liver slice cocultures of rat, dog, and human tissues. Toxicol Appl Pharmacol 244: 354-365, 2010.
42. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54: 980-986, 2005.
43. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. Prohepcidin localises to the Golgi compartment and secretory pathway in hepatocytes. J Hepatol 43: 720-728, 2005.
44. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 10: 2411-2422, 1996.